Comparison of Hydrogels for the Development of Well-Defined 3D Cancer Models of Breast Cancer and Melanoma.
biofabrication
breast cancer
hydrogel
melanoma
tumor heterogeneity
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
17 Aug 2020
17 Aug 2020
Historique:
received:
09
07
2020
revised:
10
08
2020
accepted:
14
08
2020
entrez:
23
8
2020
pubmed:
23
8
2020
medline:
23
8
2020
Statut:
epublish
Résumé
Bioprinting offers the opportunity to fabricate precise 3D tumor models to study tumor pathophysiology and progression. However, the choice of the bioink used is important. In this study, cell behavior was studied in three mechanically and biologically different hydrogels (alginate, alginate dialdehyde crosslinked with gelatin (ADA-GEL), and thiol-modified hyaluronan (HA-SH crosslinked with PEGDA)) with cells from breast cancer (MDA-MB-231 and MCF-7) and melanoma (Mel Im and MV3), by analyzing survival, growth, and the amount of metabolically active, living cells via WST-8 labeling. Material characteristics were analyzed by dynamic mechanical analysis. Cell lines revealed significantly increased cell numbers in low-percentage alginate and HA-SH from day 1 to 14, while only Mel Im also revealed an increase in ADA-GEL. MCF-7 showed a preference for 1% alginate. Melanoma cells tended to proliferate better in ADA-GEL and HA-SH than mammary carcinoma cells. In 1% alginate, breast cancer cells showed equally good proliferation compared to melanoma cell lines. A smaller area was colonized in high-percentage alginate-based hydrogels. Moreover, 3% alginate was the stiffest material, and 2.5% ADA-GEL was the softest material. The other hydrogels were in the same range in between. Therefore, cellular responses were not only stiffness-dependent. With 1% alginate and HA-SH, we identified matrices that enable proliferation of all tested tumor cell lines while maintaining expected tumor heterogeneity. By adapting hydrogels, differences could be accentuated. This opens up the possibility of understanding and analyzing tumor heterogeneity by biofabrication.
Identifiants
pubmed: 32824576
pii: cancers12082320
doi: 10.3390/cancers12082320
pmc: PMC7465483
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Deutsche Forschungsgemeinschaft
ID : Project number 326998133 - TRR 225 (subprojects A01, A02, A07, C02, C03)
Références
Biomaterials. 2004 Mar-Apr;25(7-8):1339-48
pubmed: 14643608
FASEB J. 2018 Oct;32(10):5587-5601
pubmed: 29746168
J Mater Chem B. 2017;5(41):8183-8192
pubmed: 29354263
Biofabrication. 2020 Jul 09;12(4):045004
pubmed: 32485692
Biomolecules. 2019 Sep 01;9(9):
pubmed: 31480599
J Mater Sci Mater Med. 2018 Dec 29;30(1):8
pubmed: 30594988
Science. 2011 Mar 25;331(6024):1559-64
pubmed: 21436443
Int J Cancer. 2007 Jun 15;120(12):2557-67
pubmed: 17315194
J Dermatol Sci. 1996 Jun;12(2):118-26
pubmed: 8814543
Curr Protoc Cell Biol. 2008 Sep;Chapter 10:Unit 10.14
pubmed: 18819087
Sci Rep. 2019 Jul 24;9(1):10722
pubmed: 31341222
Oncotarget. 2015 Jan 1;6(1):570-83
pubmed: 25402435
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Biomaterials. 2002 Sep;23(18):3825-31
pubmed: 12164186
Int J Cancer. 2011 Mar 15;128(6):1303-15
pubmed: 20473947
Biofabrication. 2017 Nov 14;9(4):044108
pubmed: 28906257
PLoS One. 2014 Sep 30;9(9):e107952
pubmed: 25268892
Macromol Biosci. 2019 Sep;19(9):e1900245
pubmed: 31386277
Phys Med Biol. 2003 Jul 21;48(14):2183-98
pubmed: 12894978
Nat Rev Drug Discov. 2004 Aug;3(8):711-5
pubmed: 15286737
Tumour Biol. 1995;16(4):222-9
pubmed: 7604203
Sci Rep. 2017 Dec 6;7(1):17042
pubmed: 29213126
Physiol Rev. 2011 Jan;91(1):221-64
pubmed: 21248167
Biomacromolecules. 2006 May;7(5):1471-80
pubmed: 16677028
Med Sci Monit. 2009 Feb;15(2):RA32-40
pubmed: 19182722
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
Biofabrication. 2019 Dec 31;12(1):015024
pubmed: 31404917
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Cancer. 2008 Dec 15;113(12):3341-8
pubmed: 18988292
Cells. 2019 Oct 22;8(10):
pubmed: 31652536
J Cell Physiol. 1994 Aug;160(2):275-86
pubmed: 7518822
Cytoskeleton (Hoboken). 2011 Dec;68(12):671-93
pubmed: 22031535
J Carcinog. 2008 Jul 16;7:1
pubmed: 18631381
Int J Cancer. 1991 Apr 22;48(1):85-91
pubmed: 2019461
Polymers (Basel). 2019 Sep 27;11(10):
pubmed: 31569810
Cancers (Basel). 2018 Dec 03;10(12):
pubmed: 30513961
Nature. 2002 Jun 27;417(6892):949-54
pubmed: 12068308
Front Immunol. 2015 Jun 02;6:261
pubmed: 26082778
Biofabrication. 2020 Jul 09;12(4):045005
pubmed: 32485696
Biochem Mol Biol Int. 1998 Dec;46(5):1043-53
pubmed: 9861458
BMC Cancer. 2013 Apr 05;13:181
pubmed: 23560496
Sci Adv. 2017 Sep 13;3(9):e1700764
pubmed: 28924608
J Cutan Pathol. 2020 Feb;47(2):139-145
pubmed: 31677173
Exp Cell Res. 2015 Sep 10;337(1):1-15
pubmed: 26222208
Materials (Basel). 2014 Mar 06;7(3):1957-1974
pubmed: 28788549
Front Immunol. 2019 May 10;10:947
pubmed: 31134064
Carbohydr Polym. 2019 May 1;211:336-348
pubmed: 30824098
J Mech Behav Biomed Mater. 2013 Nov;27:115-27
pubmed: 23916408
PLoS One. 2015 Aug 12;10(8):e0135426
pubmed: 26267486
Cancer Biol Med. 2019 May;16(2):299-311
pubmed: 31516750
Artif Organs. 2013 Feb;37(2):166-74
pubmed: 23067437
Cell. 2000 Jan 7;100(1):57-70
pubmed: 10647931
Oncol Lett. 2017 Jun;13(6):4708-4712
pubmed: 28588725
Isr Med Assoc J. 2004 Dec;6(12):753-5
pubmed: 15609889
Nat Rev Cancer. 2001 Oct;1(1):46-54
pubmed: 11900251
J Biomed Mater Res A. 2006 Dec 15;79(4):902-12
pubmed: 16941590
Proc Inst Mech Eng H. 2018 Apr;232(4):323-343
pubmed: 29506427
Front Immunol. 2015 Apr 14;6:169
pubmed: 25926834
J Mater Chem B. 2014 Mar 21;2(11):1470-1482
pubmed: 32261366
Oncogene. 2018 Feb 15;37(7):897-911
pubmed: 29059159
Int J Cancer. 2007 Jun 15;120(12):2590-9
pubmed: 17290393
Int J Cancer. 1995 Mar 3;60(5):668-75
pubmed: 7532159
Int J Oncol. 2017 Mar;50(3):993-1001
pubmed: 28197635